A 34 years old female, she who is a preemie, conceived by IVF conception, currently 15 weeks gestation. Presented with a history of? A fever for past four days. Also she has history of loose stools. Initially for two days, and later symptoms of diarrhea settled, and she's on treatment like injections of Trioxone for past three days. Still she's continuing to get fever. Every afternoon. Of 100 degree temperature. She's history of atrial- Like rashes. On and off, she develops. Her CRP is around 60. What investigations to be... Madam, to her urine culture is no growth. What, what kind of management can we proceed with this case? How to proceed with this case? That's all.
Reading File
Finding Sources
Finding Sources
Searching PubMed
fever pregnancy second trimester diagnosis management
Reading File
Finding Sources
Finding Sources
Searching PubMed
lupus flare pregnancy management
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Searching the Web
SLE lupus diagnosis pregnancy fever rash ANA investigations management 2024
I now have a strong evidence base. Let me compile a comprehensive, structured answer for this complex clinical scenario.
This is a fascinating and clinically challenging case. Here is a structured analysis:
Clinical Summary & Key Diagnostic Clues
Patient: 34F, 15 weeks pregnant (IVF-conceived, premature herself), with:
- Fever for 4 days, initially with diarrhea (now resolved)
- On Ceftriaxone (Trioxone) for 3 days - fever persisting
- Episodic/atypical rash (described as "atrial-like" - likely malar/butterfly rash)
- CRP ~60
- Urine culture: no growth
The Clinical Alarm: What This Picture Suggests
The combination of recurrent rash + fever + pregnancy + IVF conception is highly suggestive of Systemic Lupus Erythematosus (SLE) - either:
- New/undiagnosed SLE presenting in pregnancy, OR
- Known SLE with a flare triggered by pregnancy
The key clues are:
- Malar ("butterfly") rash - on and off, which is classic for SLE
- Fever that is NOT responding to broad-spectrum antibiotics (Ceftriaxone)
- Elevated CRP (~60) - inflammatory, not clearly infectious
- Urine culture negative (rules out UTI/pyelonephritis)
- IVF-conceived - women with autoimmune disease often have subfertility
- History of being a preemie - possible hereditary connective tissue/autoimmune background
The diarrhea that resolved early may have been a viral prodrome or a GI manifestation of the same inflammatory process. The persistent afternoon fever (quotidian/afternoon pattern) is very characteristic of SLE or other autoimmune/inflammatory conditions, not typical bacterial sepsis.
Immediate Investigations to Order
Serological / Autoimmune Panel (Priority 1)
| Test | Rationale |
|---|---|
| ANA (Antinuclear Antibody) | Screening test - positive in >95% of SLE |
| Anti-dsDNA antibody | Highly specific for SLE; correlates with disease activity |
| Anti-Sm antibody | Highly specific for SLE |
| Complement C3 & C4 | Low in active SLE flare (consumed); helps distinguish from preeclampsia |
| Antiphospholipid antibodies (aPL): Lupus anticoagulant, Anticardiolipin IgG/IgM, Anti-β2GP1 | Critical in pregnancy - APS causes recurrent loss and thrombosis |
| Anti-Ro/SSA & Anti-La/SSB | Risk of neonatal lupus and congenital heart block - mandatory in pregnancy |
Haematology & Biochemistry
| Test | Rationale |
|---|---|
| CBC with differential | Leukopenia, lymphopenia, thrombocytopenia are SLE criteria |
| LFTs | SLE hepatitis vs HELLP (though too early for HELLP at 15 weeks) |
| Serum creatinine + eGFR | Lupus nephritis assessment |
| 24-hour urine protein or spot urine PCR | Lupus nephritis |
| Urine microscopy with casts | RBC casts = nephritis |
| LDH, haptoglobin, peripheral smear | Hemolytic anemia (Coombs-positive hemolysis in SLE) |
| Serum ferritin | Markedly elevated in macrophage activation syndrome (MAS), a severe SLE complication |
Infection Screen (to exclude before immunosuppression)
| Test | Rationale |
|---|---|
| Blood cultures x2 | Before any change in antibiotics |
| Widal test / Typhidot / Blood culture for Salmonella | Enteric fever - fever + diarrhea + ceftriaxone partially treating, but 3 days may not be enough; however persistent fever suggests non-infectious cause |
| Dengue NS1 Ag + IgM/IgG | Dengue causes fever + rash + thrombocytopenia |
| Malaria smear/RDT | Rule out if endemic area |
| Serum Procalcitonin | Helps differentiate bacterial (high) from autoimmune (usually normal/mildly elevated) fever |
| HIV, Hepatitis B/C serology | Standard in pregnancy and before immunosuppression |
| TORCH panel | Toxoplasma, Rubella, CMV, HSV - all can cause fever + rash in pregnancy |
Imaging
- Fetal Doppler + Obstetric ultrasound - Assess fetal wellbeing at 15 weeks
- Fetal echocardiogram at 16-26 weeks (if anti-Ro/SSA positive, to screen for congenital heart block)
- Chest X-ray (with shielding) if pulmonary SLE or pleuritis is suspected
Management Plan
Step 1 - Stop and Re-Evaluate Antibiotics
- Ceftriaxone (Trioxone) is not treating this effectively. After 3 days with persistent fever and no growth on cultures, the probability of a bacterial cause is significantly falling.
- Do not empirically escalate antibiotics without microbiological evidence.
- Blood cultures must be sent before any antibiotic change.
Step 2 - Multidisciplinary Team (MDT)
This patient must be co-managed by:
- Rheumatologist (primary lead for SLE diagnosis and treatment)
- Maternal-Fetal Medicine (MFM) / High-Risk Obstetrician
- Nephrologist if lupus nephritis is confirmed
- Pediatric cardiologist if congenital heart block risk identified
Step 3 - If SLE/Lupus Flare Confirmed
Safe medications in pregnancy for SLE flare:
| Drug | Use | Safety in Pregnancy |
|---|---|---|
| Hydroxychloroquine (HCQ) 200-400 mg/day | Maintenance + flare prevention | Safe; should be continued throughout; reduces flare risk |
| Prednisolone (non-fluorinated) | Active flare management | Safe at lowest effective dose; avoid high doses |
| Azathioprine | Steroid-sparing, maintenance | Safe in pregnancy |
| Low-dose Aspirin 75-150 mg/day | Preeclampsia prevention + APS | Recommended for all SLE pregnancies |
| LMWH (if APS positive) | Thrombosis prevention | Mandatory if aPL positive |
Drugs to AVOID:
- Methotrexate (teratogenic)
- Mycophenolate mofetil (teratogenic)
- Cyclophosphamide (in first/second trimester)
- NSAIDs (after 20 weeks)
Step 4 - Monitoring During This Pregnancy
- Weekly antenatal visits
- Serial anti-dsDNA + complement (C3/C4) levels every 4-6 weeks (rising dsDNA + falling complement = flare signal)
- Fetal growth scans from 18 weeks (2-3 weekly if growth restriction suspected)
- Blood pressure monitoring (home BP after 20 weeks)
- Fetal echocardiogram at 20-24 weeks (if anti-Ro/SSA +ve)
- Urine PCR/24h protein at each visit
Differential Diagnoses to Consider Alongside SLE
- Adult-onset Still's Disease (AOSD) - Quotidian fever, salmon-colored rash, high ferritin - can resemble SLE; rash in AOSD appears WITH fever spikes
- Dengue fever - Rash + fever + thrombocytopenia; check NS1 antigen
- Enteric fever (Typhoid) - Rose spots are a feature; but 3 days of Ceftriaxone without defervescence makes untreated typhoid less likely; though multidrug-resistant typhoid is increasing
- Viral infection - CMV, EBV (monospot test)
- Antiphospholipid Syndrome (APS) alone - Without full SLE criteria
Key Message for Clinical Practice
The triad of recurrent rash + fever not responding to antibiotics + pregnancy should prompt an immediate autoimmune/rheumatological workup. In this patient, SLE must be actively excluded before continuing empirical antibiotic escalation. Critically, complement levels (C3/C4) and anti-dsDNA are the dynamic markers that distinguish an SLE flare from infection in pregnancy. Hydroxychloroquine is safe and beneficial throughout gestation.
Textbook source: Creasy & Resnik's Maternal-Fetal Medicine, Chapter on SLE and Pregnancy - "Flare is most confidently diagnosed when a pregnant patient has new or increasing characteristic rash (not erythema alone), lymphadenopathy, arthritis, fever..." and "Disease flares are managed with nonfluorinated glucocorticoids and, if necessary, immunosuppressive agents compatible with pregnancy."
Recent evidence: A 2024 systematic review in Lancet Rheumatology (PMID 39153486) confirmed that active disease and complement abnormalities are the strongest predictors of adverse pregnancy outcomes in SLE. A 2024 EULAR guidelines update also reinforces hydroxychloroquine use throughout gestation.
This is a shared conversation. Sign in to Orris to start your own chat.